Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Brokerages

Certara, Inc. (NASDAQ:CERT) has received a consensus recommendation of “Hold” from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.45.

CERT has been the topic of a number of recent research reports. Weiss Ratings raised Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. Barclays boosted their target price on shares of Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Finally, UBS Group restated a “neutral” rating and issued a $10.00 price target on shares of Certara in a report on Wednesday.

Certara Price Performance

CERT stock opened at $9.34 on Friday. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The company has a 50-day moving average price of $8.24 and a 200 day moving average price of $6.74. The stock has a market cap of $1.42 billion, a PE ratio of -20.76 and a beta of 1.42.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. During the same period last year, the company earned $0.07 EPS. The business’s revenue was down 10.8% compared to the same quarter last year. Equities research analysts anticipate that Certara will post 0.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC purchased a new position in shares of Certara during the second quarter worth $39,000. NorthRock Partners LLC acquired a new stake in Certara during the 2nd quarter worth about $68,000. State of Wyoming purchased a new position in shares of Certara during the 2nd quarter valued at about $72,000. Pacer Advisors Inc. raised its stake in shares of Certara by 28.1% during the 1st quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after buying an additional 2,871 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new position in shares of Certara in the 1st quarter valued at about $78,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara (NASDAQ:CERT) provides software and technology-enabled services that support the development, approval and commercialization of medicines. The company specializes in model-informed drug development, using pharmacometrics, simulation, data analysis and regulatory science to help biopharmaceutical companies evaluate drug safety, efficacy, dosing and potential regulatory outcomes.

Its software portfolio includes platforms such as Simcyp, which supports clinical pharmacology and drug-interaction modeling; Phoenix, used for pharmacokinetic and pharmacodynamic analysis; and Pinnacle 21, which helps organizations manage clinical data standards and regulatory submissions.